Bond stimulated engineered macrophages with light, then made the cells wait for different periods of time. She then presented them with the mock cancer cells, this time displaying that IgG "eat me ...

The drug that they designed already has a licence, which they say should hasten the approval process ... it stops cancer cells from hiding and sending out "eat me not" signals to macrophages.

Higher levels of omega-6 fatty acids often found in ultraprocessed foods may interfere with the immune system’s fight against ...

Rac2 is one component of the complex eating process. Rac helps the eating ... In her talk she described programming ...

Understanding the signaling pathways that control macrophage behavior is critical for designing new therapies. “Ultimately, I try to get immune cells to eat cancer,” Morrissey said. “To do this, we ...

Cancer cells impair monocyte-mediated T-cell activation by disrupting inflammatory pathways in the tumor microenvironment.

Two main sub-types of immune cells are T cells and macrophages. T cells are designed to recognise the molecular signatures of particular proteins, such as those from bacteria, in order to activate an ...

It is thought that blockade of that interaction can restore the ability of macrophages to phagocytose or 'eat' cancer cells and – crucially – may offer a new option for the sizeable proportion ...

Carisma Therapeutics is developing a unique, differentiated immuno-oncology (IO) treatment for solid tumors based on chimeric antigen receptor macrophages (CAR-M). Current IO treatments have ...